Understand what your hormone testing results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
GH deficiency and the markers that hint at it
GH deficiency biomarkers are blood signals that show how well the body’s growth-hormone system is working. Growth hormone (GH, somatotropin) is released from the anterior pituitary (somatotrophs) in short bursts and vanishes quickly, so a single GH level rarely captures the true picture. Instead, testing focuses on the steadier messengers made in response to GH—mainly insulin-like growth factor 1 (IGF‑1) and its carrier protein IGF‑binding protein‑3 (IGFBP‑3), produced largely by the liver (hepatocytes) with support from the acid‑labile subunit (ALS). These downstream markers integrate GH activity over time, acting as a durable readout of the somatotropic axis. Measuring them helps determine whether growth signaling to bones, muscles, and metabolism is adequate, establishes an objective baseline, and tracks how the system responds over time to treatment. Together, they translate the fleeting GH pulse into a stable biological story—how effectively the pituitary’s signal is being generated, transported, and received across the body.
Why IGF-1 tells a steadier story than GH
GH deficiency testing focuses on the GH–IGF‑1 axis. Because GH is secreted in pulses, steady blood markers—insulin‑like growth factor‑1 (IGF‑1), and in children IGFBP‑3—best reflect overall GH activity across systems that govern growth, body composition, bone turnover, metabolism, and cardiovascular health. IGF‑1 is read against age‑ and sex‑specific ranges or a Z‑score. In adults, healthy values cluster around the mid‑range for age; values near or below the lower limit suggest impaired GH action, while very high values point to GH excess, not deficiency. When IGF‑1 is low for age, it usually reflects reduced GH secretion or bioactivity. Physiology shifts toward less protein building and fat breakdown, raising visceral fat, lowering lean mass, and slowing bone remodeling. Adults feel fatigue, reduced strength and stamina, larger waistlines, worse lipids, and bone loss. Children show slow linear growth and delayed skeletal maturation. Pregnancy relies on placental GH and rising IGF‑1, so results must be interpreted in that physiologic context. An elevated IGF‑1 typically rules out GH deficiency and raises concern for GH excess, which can produce soft‑tissue swelling, headaches, sleep apnea, insulin resistance, and cardiometabolic risk. Big picture, IGF‑1 bridges nutrition, thyroid and liver function, and pituitary output. Read with GH stimulation tests and clinical features, it links the GH axis to muscle, bone, fat, and heart health, clarifying risks like osteoporosis, visceral adiposity, and cardiovascular disease.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers from home
One blood draw. A full picture of your health, explained in plain language.
The honest limits of GH screening blood work
Growth hormone (GH) deficiency blood testing provides insight into how well your body supports growth, tissue repair, metabolism, and overall vitality. GH is a key hormone that influences energy levels, muscle and bone strength, cardiovascular health, cognitive function, and immune resilience. At Superpower, we assess GH status by measuring a specific biomarker: IGF-1.IGF-1, or insulin-like growth factor 1, is a protein produced mainly in the liver in response to GH stimulation. Because GH itself is released in pulses and can be difficult to measure directly, IGF-1 serves as a stable indicator of average GH activity over time. Low IGF-1 levels can suggest GH deficiency, while normal or high levels generally indicate adequate GH function. A healthy IGF-1 level reflects the body’s ability to maintain stable growth, repair tissues, and regulate metabolism. When IGF-1 is within the expected range for age and sex, it supports the body’s capacity for cellular renewal, muscle maintenance, and metabolic balance. In the context of GH deficiency, low IGF-1 may signal reduced anabolic (building) processes and can be associated with symptoms like fatigue, decreased muscle mass, and changes in body composition. It’s important to note that IGF-1 levels naturally decline with age and can be influenced by factors such as acute illness, chronic disease, pregnancy, nutritional status, and certain medications. Laboratory methods and reference ranges may also vary, so results are best interpreted in context.
Frequently Asked Questions
References
- Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML (2011). Evaluation and treatment of adult growth hormone deficiency: An Endocrine Society clinical practice guideline. *The Journal of Clinical Endocrinology and Metabolism*, *96*(6), 1587-1609. https://doi.org/10.1210/jc.2011-0179
- Yuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, Hoffman AR (2019). American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. *Endocrine Practice*, *25*(11), 1191-1232. https://doi.org/10.4158/GL-2019-0405
- Clemmons DR (2011). Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. *Clinical Chemistry*, *57*(4), 555-559. https://doi.org/10.1373/clinchem.2010.150631
- National Institute of Diabetes and Digestive and Kidney Diseases. (2021). *Acromegaly*. https://www.niddk.nih.gov/health-information/endocrine-diseases/acromegaly
- MedlinePlus. (n.d.). *Growth hormone deficiency*. https://medlineplus.gov/ency/article/001176.htm
